Cancer Research TCM Europe Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Jong, A.
Right arrow Articles by Offringa, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Jong, A.
Right arrow Articles by Offringa, R.
[Cancer Research 62, 472-479, January 15, 2002]
© 2002 American Association for Cancer Research

Immunology

Frequent Detection of Human Papillomavirus 16 E2-specific T-helper Immunity in Healthy Subjects1

Annemieke de Jong2, Sjoerd H. van der Burg2,,3, Kitty M. C. Kwappenberg, Jeanette M. van der Hulst, Kees L. M. C. Franken, Annemieke Geluk, Krista E. van Meijgaarden, Jan Wouter Drijfhout, Gemma Kenter, Pieter Vermeij, Cornelis J. M. Melief and Rienk Offringa

Departments of Immunohematology and Blood Transfusion [A. d. J., S. H. v. d. B., K. M. C. K., J. M. v. d. H., K. L. M. C. F., A. G., K. E. v. M., J. W. D., C. J. M. M., R. O.], Gynecology [G. K.], and Clinical Pharmacy and Toxicology [A. d. J., P. V.], Leiden University Medical Center, 2300 RC Leiden, the Netherlands

The incidence of genital human papillomavirus (HPV) infections is high in young, sexually active individuals. Most infections are cleared within 1 year after infection. The targets for the cellular immune response in this process of viral clearance remain to be identified, but the expression pattern of the E2 protein in early infection and low-grade cervical intraepithelial neoplasia renders this early protein a candidate antigen. Therefore, we studied the HPV16 E2-specific T-cell responses in more detail. Very strong proliferative responses against one or more peptide-epitopes derived from this antigen can be found in peripheral blood mononuclear cell cultures of approximately half of the healthy donors. Additional analysis revealed that at least a majority of these responses represent reactivity by memory CD4+ T-helper (Th) 1-type cells capable of secreting IFN-{gamma} on antigenic stimulation. Interestingly, all of the E2 peptides against which strong responses were detected are clustered in the key functional domains of the E2 protein, which are conserved to considerable extent between HPV types. This suggests that HPV16 E2-specific Th memory may be installed through encounter with HPV types other than HPV16. Indeed, one HPV16 E2-specific Th clone was found to cross-react against homologuous peptides from other HPV types, but three other Th clones failed to show similar cross-reactivity. Therefore, part of the HPV16 E2-specific Th memory may relate to previous encounter of other HPV types, whereas the majority of the immune repertoire concerned is most likely established through infection with HPV16 itself. Our data are the first to reveal that the T-cell repertoire of healthy donors can contain particularly high frequencies of E2-specific memory Th cells and suggest that boosting of this immunity can be used for preventive and therapeutic vaccination against HPV-induced lesions.




This article has been cited by other articles:


Home page
 NEJMHome page
G. G. Kenter, M. J.P. Welters, A. R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al.
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
N. Engl. J. Med., November 5, 2009; 361(19): 1838 - 1847.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. de Vos van Steenwijk, S. J. Piersma, M. J.P. Welters, J. M. van der Hulst, G. Fleuren, B. W.J. Hellebrekers, G. G. Kenter, and S. H. van der Burg
Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response
Clin. Cancer Res., November 15, 2008; 14(22): 7188 - 7195.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
D S Hughes, N Powell, and A N Fiander
Will vaccination against human papillomavirus prevent eye disease? A review of the evidence
Br J Ophthalmol, April 1, 2008; 92(4): 460 - 465.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. G. Kenter, M. J.P. Welters, A.R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al.
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
Clin. Cancer Res., January 1, 2008; 14(1): 169 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J.P. Welters, G. G. Kenter, S. J. Piersma, A. P.G. Vloon, M. J.G. Lowik, D. M.A. Berends-van der Meer, J. W. Drijfhout, A. R. P.M. Valentijn, A. R. Wafelman, J. Oostendorp, et al.
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine
Clin. Cancer Res., January 1, 2008; 14(1): 178 - 187.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Seresini, M. Origoni, F. Lillo, L. Caputo, A. M. Paganoni, S. Vantini, R. Longhi, G. Taccagni, A. Ferrari, C. Doglioni, et al.
IFN-{gamma} Produced by Human Papilloma Virus-18 E6-Specific CD4+ T Cells Predicts the Clinical Outcome after Surgery in Patients with High-Grade Cervical Lesions
J. Immunol., November 15, 2007; 179(10): 7176 - 7183.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al.
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens
PNAS, July 17, 2007; 104(29): 12087 - 12092.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
K. M. E. Gallagher and S. Man
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women
J. Gen. Virol., May 1, 2007; 88(5): 1470 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Peng, C. Trimble, L. Wu, D. Pardoll, R. Roden, C.-F. Hung, and T.-C. Wu
HLA-DQB1*02-Restricted HPV-16 E7 Peptide-Specific CD4+ T-Cell Immune Responses Correlate with Regression of HPV-16-Associated High-Grade Squamous Intraepithelial Lesions
Clin. Cancer Res., April 15, 2007; 13(8): 2479 - 2487.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
S. Dillon, T. Sasagawa, A. Crawford, J. Prestidge, M. K. Inder, J. Jerram, A. A. Mercer, and M. Hibma
Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2
J. Gen. Virol., March 1, 2007; 88(3): 803 - 813.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. J. Piersma, E. S. Jordanova, M. I.E. van Poelgeest, K. M.C. Kwappenberg, J. M. van der Hulst, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, G. J. Fleuren, R. Offringa, et al.
High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer
Cancer Res., January 1, 2007; 67(1): 354 - 361.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Paschen, M. Song, W. Osen, X. D. Nguyen, J. Mueller-Berghaus, D. Fink, N. Daniel, M. Donzeau, W. Nagel, H. Kropshofer, et al.
Detection of Spontaneous CD4+ T-Cell Responses in Melanoma Patients against a Tyrosinase-Related Protein-2-Derived Epitope Identified in HLA-DRB1*0301 Transgenic Mice
Clin. Cancer Res., July 15, 2005; 11(14): 5241 - 5247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. I.E. van Poelgeest, M. van Seters, M. van Beurden, K. M.C. Kwappenberg, C. Heijmans-Antonissen, J. W. Drijfhout, C. J.M. Melief, G. G. Kenter, T. J.M. Helmerhorst, R. Offringa, et al.
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment
Clin. Cancer Res., July 15, 2005; 11(14): 5273 - 5280.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. L. Smith, A. Tristram, K. M. Gallagher, A. N. Fiander, and S. Man
Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18
Int. Immunol., February 1, 2005; 17(2): 167 - 176.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. de Jong, M. I. E. van Poelgeest, J. M. van der Hulst, J. W. Drijfhout, G. J. Fleuren, C. J. M. Melief, G. Kenter, R. Offringa, and S. H. van der Burg
Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6
Cancer Res., August 1, 2004; 64(15): 5449 - 5455.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. J. Baldwin, S. H. van der Burg, C. M. Boswell, R. Offringa, J. K. Hickling, J. Dobson, J. St. C. Roberts, J. A. Latimer, R. P. Moseley, N. Coleman, et al.
Vaccinia-Expressed Human Papillomavirus 16 and 18 E6 and E7 as a Therapeutic Vaccination for Vulval and Vaginal Intraepithelial Neoplasia
Clin. Cancer Res., November 1, 2003; 9(14): 5205 - 5213.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
E. J. Davidson, P. Sehr, R. L. Faulkner, J. L. Parish, K. Gaston, R. A. Moore, M. Pawlita, H. C. Kitchener, and P. L. Stern
Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia
J. Gen. Virol., August 1, 2003; 84(8): 2089 - 2097.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
S. S. Wang and A. Hildesheim
Chapter 5: Viral and Host Factors in Human Papillomavirus Persistence and Progression
J Natl Cancer Inst Monographs, June 1, 2003; 2003(31): 35 - 40.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. Nilges, H. Hohn, H. Pilch, C. Neukirch, K. Freitag, P. J. Talbot, and M. J. Maeurer
Human Papillomavirus Type 16 E7 Peptide-Directed CD8+ T Cells from Patients with Cervical Cancer Are Cross-Reactive with the Coronavirus NS2 Protein
J. Virol., May 1, 2003; 77(9): 5464 - 5474.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. P. Welters, A. de Jong, S. J. F. van den Eeden, J. M. van der Hulst, K. M. C. Kwappenberg, S. Hassane, K. L. M. C. Franken, J. W. Drijfhout, G. J. Fleuren, G. Kenter, et al.
Frequent Display of Human Papillomavirus Type 16 E6-specific Memory T-Helper Cells in the Healthy Population as Witness of Previous Viral Encounter
Cancer Res., February 1, 2003; 63(3): 636 - 641.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.